Grade 3/4 hematological and nonhematological treatment side-effects stratified according to randomization group
Side effects . | 2-CdA, no. (%) . | CC, no. (%) . | CMC, no. (%) . | P . |
|---|---|---|---|---|
| Neutropenia | 32 (19) | 50 (32) | 57 (38) | .001 |
| Thrombocytopenia | 31 (19) | 28 (17) | 36 (24) | .47 |
| Anemia (including AIHA) | 21 (13) | 19 (12) | 13 (9) | .27 |
| Infections and FUO | 45 (27) | 55 (34) | 60 (40) | .057 |
| Vomiting | 0 (0) | 3 (2) | 4 (3) | .11 |
| Alopecia | 0 (0) | 0 (0) | 1 (1) | .96 |
| Aminotransferases increased | 0 (0) | 0 (0) | 1 (1) | .96 |
| Richter syndrome | 1 (1) | 2 (1) | 1 (1) | .52 |
| Secondary neoplasms | 2 (1) | 6 (4) | 7 (4) | .57 |
Side effects . | 2-CdA, no. (%) . | CC, no. (%) . | CMC, no. (%) . | P . |
|---|---|---|---|---|
| Neutropenia | 32 (19) | 50 (32) | 57 (38) | .001 |
| Thrombocytopenia | 31 (19) | 28 (17) | 36 (24) | .47 |
| Anemia (including AIHA) | 21 (13) | 19 (12) | 13 (9) | .27 |
| Infections and FUO | 45 (27) | 55 (34) | 60 (40) | .057 |
| Vomiting | 0 (0) | 3 (2) | 4 (3) | .11 |
| Alopecia | 0 (0) | 0 (0) | 1 (1) | .96 |
| Aminotransferases increased | 0 (0) | 0 (0) | 1 (1) | .96 |
| Richter syndrome | 1 (1) | 2 (1) | 1 (1) | .52 |
| Secondary neoplasms | 2 (1) | 6 (4) | 7 (4) | .57 |
There were 166 patients in the 2-CdA group, 162 in the CC group, and 151 in the CMC group.
AIHA indicates autoimmune hemolytic anemia; FUO, fever of unknown origin.